MediciNova Inc.’s (MNOV) phase II trial results of MN-166 (ibudilast) in opioid dependence have been encouraging.
Forex – financial instrument.Forex news
MediciNova Inc.’s (MNOV) phase II trial results of MN-166 (ibudilast) in opioid dependence have been encouraging.